{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:55:49Z","timestamp":1765554949282,"version":"3.41.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The aim of the present study was to appraise retrospectively the influence of valproate (VPA) and antidepressants (ADs) on the steady-state plasma concentrations of clozapine (CLZ), the prototype of various second-generation antipsychotics, norclozapine (NCLZ, its main metabolite), and their ratio (NCLZ:CLZ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Sixty-seven psychotic patients with a prevalent diagnosis of bipolar disorder were studied. We then analyzed data altogether and subdivided them into 4 groups, according to pharmacological treatments: #1 CLZ (n = 21), #2 CLZ plus ADs (n = 13), #3 CLZ plus VPA (n = 16), and #4 CLZ plus ADs plus VPA (n = 17).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>First, significant positive between CLZ and NCLZ plasma levels (in nanograms\/milliliter) and the drug daily dosages (in milligrams\/kilogram of body weight) (n = 67) were observed (Spearman: rCLZ = 0.49; rNCLZ = 0.61;<jats:italic toggle=\"yes\">P<\/jats:italic>&lt; 0.001). We then normalized by given doses CLZ and NCLZ plasma levels, natural log transformed them, and performed analysis of variance factor analyses followed by pairwise comparisons, performed on the 4 groups and the 3 CLZ parameters. We identified significant drug effects on (1) CLZ plasma levels, significantly higher in group #2 versus group #1, and (2) NCLZ:CLZ ratio, lower in group #2 versus groups #1 and #3. Significant drug \u00d7 gender interactions were observed in group #3, showing higher NCLZ levels and NCLZ:CLZ ratios in men compared with women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Despite its inherent limitations, this observational study confirms the significant increase in plasma CLZ concentrations and reduction in NCLZ:CLZ ratio when this drug was coadministered with ADs (group #2), an effect apparently counteracted by VPA (group #4). The drug \u00d7 gender interactions in patients taking both CLZ and VPA (group #3) warrant further prospective study.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000513","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T21:30:50Z","timestamp":1522359050000},"page":"443-451","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Valproate and Antidepressant Drugs on Clozapine Metabolism in Patients With Psychotic Mood Disorders"],"prefix":"10.1097","volume":"40","author":[{"given":"Donatella","family":"Marazziti","sequence":"first","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionella","family":"Palego","sequence":"additional","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Betti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Pisa, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino","family":"Giannaccini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Pisa, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Massimetti","sequence":"additional","affiliation":[{"name":"ASST Bergamo Ovest: SSD Servizio Psichiatrico diagnosi e cura, Ospedale Treviglio, Treviglio, Bergamo, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Baroni","sequence":"additional","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ciapparelli","sequence":"additional","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lucacchini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Pisa, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mucci","sequence":"additional","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Dell'Osso","sequence":"additional","affiliation":[{"name":"Psychiatry Section, Department of Experimental and Clinical Medicine, University of Pisa;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann Intern Med."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective","volume":"17","author":"Dold","year":"2014","journal-title":"Evid Based Ment Health."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1176\/ps.49.12.1590","article-title":"Health status and health care costs for publicly funded patients with schizophrenia started on clozapine","volume":"49","author":"Blieden","year":"1998","journal-title":"Psychiatr Serv."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/ajp.155.6.751","article-title":"Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome","volume":"155","author":"Buchanan","year":"1998","journal-title":"Am J Psychiatry."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psychres.2009.04.001","article-title":"Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment","volume":"178","author":"Kaneda","year":"2010","journal-title":"Psychiatry Res."},{"key":"R11-20230814","first-page":"47","article-title":"Efficacy of clozapine in patients with chronic schizophrenia","volume":"1","author":"De Silva","year":"2010","journal-title":"SL J Psychiatry."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine induced agranulocytosis: incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.779","article-title":"Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?","volume":"21","author":"Kang","year":"2006","journal-title":"Hum Psychopharmacol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.1994.tb04786.x","article-title":"N-desmethylclozapine: a clozapine metabolite that suppresses haematopoiesis","volume":"86","author":"Gerson","year":"1994","journal-title":"Br J Haematol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF02246112","article-title":"Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study","volume":"117","author":"Olesen","year":"1995","journal-title":"Psychopharmacology (Berl)."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","article-title":"Will routine therapeutic drug monitoring have a place in clozapine therapy?","volume":"32","author":"Freeman","year":"1997","journal-title":"Clin Pharmacokinet."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine","volume":"24","author":"Young","year":"1998","journal-title":"Schizophr Bull."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1176\/jnp.13.2.302-a","article-title":"Clonic seizure associated with high clozapine plasma level","volume":"13","author":"Dumortier","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level relationships","volume":"1","author":"Varma","year":"2011","journal-title":"Ther Adv Psychopharmacol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur Neuropsychopharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1192\/pb.19.12.753","article-title":"The use of clozapine plasma levels in optimizing therapy","volume":"19","author":"Taylor","year":"1995","journal-title":"Psychiatr Bullettin."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0893-133X(02)00319-6","article-title":"Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia","volume":"27","author":"Fabrazzo","year":"2002","journal-title":"Neuropsychopharmacology."},{"issue":"suppl","key":"R23-20230814","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/BF00442557","article-title":"Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age","volume":"99","author":"Haring","year":"1989","journal-title":"Psychopharmacology (Berl)."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/WNF.0b013e31815cba61","article-title":"Variability of the in vivo metabolism of clozapine","volume":"31","author":"Raedler","year":"2008","journal-title":"Clin Neuropharmacol."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hup.1191","article-title":"Factors affecting inter-individual differences in clozapine response: a review and case report","volume":"26","author":"Bersani","year":"2011","journal-title":"Hum Psychopharmacol."},{"key":"R26-20230814","first-page":"17","article-title":"Genetic and clinical factors affecting plasma clozapine concentration","volume":"19","author":"Olsson","year":"2015","journal-title":"Prim Care Companion CNS Disord."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Curr Med Chem."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.schbul.a033463","article-title":"Clozapine augmentation: safety and efficacy","volume":"26","author":"Chong","year":"2000","journal-title":"Schizophr Bull."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr Opin Psychiatry."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am J Psychiatry."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bdi.12272","article-title":"Clozapine for treatment-resistant bipolar disorder: a systematic review","volume":"17","author":"Li","year":"2015","journal-title":"Bipolar Disord."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/092986709787909604","article-title":"Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring","volume":"16","author":"Musenga","year":"2009","journal-title":"Curr Med Chem."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.08m04301","article-title":"Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD","volume":"70","author":"Goldberg","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"R36-20230814","first-page":"255","article-title":"Concurrent use of clozapine and valproate in affective and psychotic disorders","volume":"55","author":"Kando","year":"1994","journal-title":"J Clin Psychiatry."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","article-title":"Serum concentrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine or valproate","volume":"151","author":"Centorrino","year":"1994","journal-title":"Am J Psychiatry."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0006-3223(94)90647-5","article-title":"Potential impact of valproic acid therapy on clozapine disposition","volume":"36","author":"Finley","year":"1994","journal-title":"Biol Psychiatry."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.152.4.650a","article-title":"Valproic acid effects on serum concentrations of clozapine and norclozapine","volume":"152","author":"Longo","year":"1995","journal-title":"Am J Psychiatry."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciol\u00e0","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CPP41003","article-title":"Therapeutic drug monitoring of clozapine and relapse\u2014a retrospective study of routine clinical data","volume":"41","author":"Ulrich","year":"2003","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2005.10.008","article-title":"Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients","volume":"30","author":"Wong","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism?","volume":"47","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1192\/bjp.171.2.109","article-title":"Pharmacokinetic interactions involving clozapine","volume":"171","author":"Taylor","year":"1997","journal-title":"Br J Psychiatry."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ps.51.2.250","article-title":"Effect of clozapine on polypharmacy","volume":"51","author":"Chong","year":"2000","journal-title":"Psychiatr Serv."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4088\/JCP.v61n0809","article-title":"Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients","volume":"61","author":"Lu","year":"2000","journal-title":"J Clin Psychiatry."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mehy.2012.12.024","article-title":"Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy","volume":"80","author":"L\u00e9gar\u00e9","year":"2013","journal-title":"Med Hypotheses."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/clinchem\/39.8.1656","article-title":"Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography","volume":"39","author":"Volpicelli","year":"1993","journal-title":"Clin Chem."},{"key":"R53-20230814","first-page":"691","article-title":"Clozapine: an atypical antipsychotic agent","volume":"8","author":"Ereshefsky","year":"1989","journal-title":"Clin Pharmacol."},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1176\/ajp.147.11.1471","article-title":"Influence of patient-related variables on clozapine plasma levels","volume":"147","author":"Haring","year":"1990","journal-title":"Am J Psychiatry."},{"key":"R55-20230814","first-page":"59","article-title":"Effect of caffeine on clozapine pharmacokinetics in healthy volunteers","volume":"49","author":"Hagg","year":"2000","journal-title":"Br J Clin Psychiatry."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0278-5846(01)00291-3","article-title":"Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients. Influence of patient-related variables","volume":"26","author":"Palego","year":"2002","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry."},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol."},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1503\/jpn.100055","article-title":"Clozapine: a distinct, poorly understood and under-used molecule","volume":"35","author":"Joober","year":"2010","journal-title":"J Psychiatry Neurosci."},{"key":"R61-20230814","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"Am J Psychiatry."},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-2000-8361","article-title":"Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline","volume":"33","author":"Spina","year":"2000","journal-title":"Pharmacopsychiatry."},{"key":"R64-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R65-20230814","first-page":"117","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics Pers Med."},{"key":"R66-20230814","first-page":"39","article-title":"Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine","volume":"12","author":"Meltzer","year":"1995","journal-title":"Neuropsychopharmacology."},{"key":"R67-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov Disord."},{"key":"R68-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.v59n0302","article-title":"Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder","volume":"59","author":"Benedetti","year":"1998","journal-title":"J Clin Psychiatry."},{"key":"R69-20230814","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.v64n0416","article-title":"Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study","volume":"64","author":"Ciapparelli","year":"2003","journal-title":"J Clin Psychiatry."},{"key":"R70-20230814","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00406-004-0528-8","article-title":"Low doses of clozapine may stabilize treatment-resistant bipolar patients","volume":"255","author":"Fehr","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"R71-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-0327(97)00160-2","article-title":"Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics","volume":"48","author":"Frye","year":"1998","journal-title":"J Affect Disord."},{"key":"R72-20230814","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1745017901006010030","article-title":"Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study","volume":"6","author":"Benedetti","year":"2010","journal-title":"Clin Pract Epidemiol Ment Health."},{"key":"R73-20230814","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1592\/phco.27.11.1599","article-title":"Augmentation of aripiprazole with low-dose clozapine","volume":"27","author":"Stoner","year":"2007","journal-title":"Pharmacotherapy."},{"key":"R74-20230814","doi-asserted-by":"crossref","first-page":"904829","DOI":"10.1155\/2014\/904829","article-title":"Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine","volume":"2014","author":"Bartolommei","year":"2014","journal-title":"ISRN Psychiatry."},{"key":"R75-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R76-20230814","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R77-20230814","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"key":"R78-20230814","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist","volume":"315","author":"Burstein","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"R79-20230814","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.npp.1300768","article-title":"N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors","volume":"30","author":"Li","year":"2005","journal-title":"Neuropsychopharmacology."},{"key":"R80-20230814","first-page":"71","article-title":"Norclozapine","volume":"3","author":"Bhandal","year":"2016","journal-title":"Int J Novel Res Healthc Nurs."},{"key":"R81-20230814","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4236\/ojpsych.2012.24036","article-title":"Relationships between clozapine and norclozapine plasma concentrations, clozapine dose, and clinical response in Tunisian patients with schizophrenia-treatment resistance","volume":"2","author":"Taieb","year":"2012","journal-title":"Open J Psychiatr."},{"key":"R82-20230814","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1479-5876-12-203","article-title":"Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics","volume":"2","author":"Li","year":"2014","journal-title":"J Transl Med."},{"key":"R83-20230814","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00007691-200004000-00009","article-title":"Simultaneous plasma level analysis of clomipramine, N-desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography","volume":"22","author":"Palego","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R84-20230814","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R85-20230814","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am J Psychiatry."},{"key":"R86-20230814","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00007691-199101000-00010","article-title":"The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography","volume":"13","author":"Lovdahl","year":"1991","journal-title":"Ther Drug Monit."},{"key":"R87-20230814","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12888-015-0536-4","article-title":"Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment","volume":"15","author":"Gee","year":"2015","journal-title":"BMC Psychiatry."},{"key":"R88-20230814","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2000-8355","article-title":"A case of pharmacokinetic interference in comedication of clozapine and valproic acid","volume":"33","author":"Conca","year":"2000","journal-title":"Pharmacopsychiatry."},{"key":"R89-20230814","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","article-title":"Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics","volume":"60","author":"Lane","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"R90-20230814","first-page":"1156","article-title":"Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl) [in German]","volume":"26","author":"Ackenheil","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"R91-20230814","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF00172957","article-title":"Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection","volume":"95","author":"Bondesson","year":"1988","journal-title":"Psychopharmacology (Berl)."},{"key":"R92-20230814","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004714-199312000-00003","article-title":"Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking","volume":"13","author":"Hasegawa","year":"1993","journal-title":"J Clin Psychopharmacol."},{"key":"R93-20230814","first-page":"30","article-title":"Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations","volume":"27","author":"Llorca","year":"2002","journal-title":"J Psychiatry Neurosci."},{"key":"R94-20230814","doi-asserted-by":"crossref","first-page":"e004216","DOI":"10.1136\/bmjopen-2013-004216","article-title":"Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine","volume":"4","author":"Tsuda","year":"2014","journal-title":"BMJ Open."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T03:14:08Z","timestamp":1751512448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000513","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}